Federal contract award
75N94018F00003
IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIAL NETWORK CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES - EVALUATION OF LARCS STUDYHHSN275201300017I/HHSN27520003
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 622310 — Specialty (except Psychiatric and Substance Abuse) Hospitals |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | HHSN275201300017I |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $639.0K |
| Current contract value | $639.0K |
| Potential contract value / ceiling | $639.0K |
| Start date | Sep 24, 2018 |
| Current end date | Jul 14, 2026 |
| Potential end date | Jul 14, 2026 |
| Latest award activity | May 22, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 22, 2025 | P00005 | $0 | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE |
| Mar 14, 2025 | P00004 | $0 | NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE: NON-SEVERABLE |
| Jan 16, 2024 | P00003 | $122.6K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE. |
| Sep 25, 2023 | P00002 | $75.0K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE. |
| Sep 28, 2021 | P00001 | $177.2K | TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS AND THE PHARMACODYNAMIC EFFECTS, CYCLE CONTROL, AND SAFETY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-ACTING INJECTABLE. |
| Sep 24, 2018 | 0 | $264.2K | IGF::OT::IGF CONTRACEPTIVE CLINICAL TRIAL NETWORK CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES - EVALUATION OF LARCS STUDYHHSN275201300017I/HHSN27520003 |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.